1-4 of 4
Durga Prasad Dash
Close
Sort by
Journal Articles

FDA Cleared Companion Diagnostics (CDx) Tests ( IDH1, IDH2 and FLT3) for Acute Myeloid Leukemia (AML) Patient Care

Durga Prasad Dash, David Dinauer
Journal: Blood
Blood (2021) 138 (Supplement 1): 4442.
https://doi.org/10.1182/blood-2021-146931
Published: 2021
Journal Articles

Possible Early Clinical Management of Systemic Mastocytosis Patients with Recently FDA Approved Drug Avapritinib By Molecular Diagnosis Using a Highly Sensitive KIT D816 Mutation Assay

Durga Prasad Dash, David Dinauer, Michael Janasik
Journal: Blood
Blood (2021) 138 (Supplement 1): 4622.
https://doi.org/10.1182/blood-2021-151962
Published: 2021
Journal Articles

Identification of a Novel BCR-ABL1 Fusion Transcript in a Chronic Myeloid Leukemia (CML) Patient By Unique Molecular Methods and Subsequent Monitoring of the Patient's Response to Tyrosine Kinase Inhibitor (TKI) Therapy

Durga Prasad Dash, PhD, Valerie Trap-stamborski, PhD, Curt Czajkowski, MT(ASCP), CLSp(MB), Daniel Rauscher, CLS (ASCP), Raju Pillai, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5453.
https://doi.org/10.1182/blood-2018-99-119219
Published: 2018
Journal Articles

A New Highly Sensitive Realtime PCR Assay with Faster Turnaround Time for Detecting IDH1 and IDH2 mutations in Acute Myeloid Leukemia (AML) Patients

Durga Prasad Dash, PhD, Laura Wise, MT(ASCP)CM, Jason Harb, PhD, Adam Knier, MB (ASCP), Muriel Boretsky, MB(ASCP)CM, Jennifer Simons, BA, Dina Berchanskiy, MS, Monika de Arruda Indig, PhD, Ajith M Joseph, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2681.
https://doi.org/10.1182/blood.V130.Suppl_1.2681.2681
Published: 2017